Increased Risk of Venous Thromboembolism in Patients With Amyotrophic Lateral Sclerosis
Results From a US Insurance Claims Database Study
Citation Manager Formats
Make Comment
See Comments

Article Information
- Received February 10, 2022
- Accepted October 10, 2022
- First Published January 19, 2023.
Author Disclosures
- Varant Kupelian, PhD,
- Emma Viscidi, PhD,
- Susan Hall, PhD,
- Li Li, MS,
- Susan Eaton, MSPH,
- Anne Dilley, PhD,
- Nicolas Currier, MD,
- Toby Ferguson, MD, PhD and
- Laura Fanning, MD
- Varant Kupelian, PhD,
None
NONE
None
NONE
NONE
NONE
Salaried employee of Biogen
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
Biogen
NONE
NONE
- Emma Viscidi, PhD,
None
NONE
None
NONE
NONE
NONE
(1) Biogen, Epidemiologist, 7 years(2) Moderna, Epidemiologist, 4 months
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
(1) Biogen(2) Moderna
NONE
NONE
- Susan Hall, PhD,
None
NONE
None
NONE
NONE
NONE
1. Moderna LLC, Director, Epidemiology—Lead, Early Stage Vaccines, 1.5 years2. Biogen, Inc., Director, Epidemiology, 7 years (employee of the company who funded this study)
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
I am currently an employee of Moderna and receive stock and stock options as part of my compensation.I was formerly an employee of Biogen (2014-2021) and received stock and stock options as part of my compensation.
NONE
NONE
- Li Li, MS,
None
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Susan Eaton, MSPH,
None
NONE
None
NONE
NONE
NONE
Biogen, Director, 9 yrs
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
1) Biogen, as part of employment
NONE
NONE
NONE
NONE
NONE
- Anne Dilley, PhD,
None
NONE
None
NONE
NONE
NONE
Biogen, 2010-2020, Senior Director, Epidemiology
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Nicolas Currier, MD,
None
NONE
None
NONE
NONE
NONE
I am currently an employee of Oncorus Inc. (as of 8/2021) and was an employee of Biogen Inc. from 7/2015-7/2021
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
NONE
NONE
NONE
NONE
NONE
NONE
- Toby Ferguson, MD, PhD and
None
NONE
None
NONE
NONE
NONE
I have been employed by Biogen in research and clinical development for approximately 9 years.
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
I hold stock in Biogen.
NONE
NONE
I hold stock in Biogen.
NONE
NONE
- Laura Fanning, MD
None
NONE
None
NONE
NONE
NONE
Biogen, Executive Medical Director, Drug Safety, 2016-present
NONE
NONE
NONE
NONE
NONE
NONE
NONE
None
Biogen
NONE
NONE
NONE
NONE
NONE
- Correspondence
Dr. Kupelian varant.kupelian{at}biogen.com
Article usage
Cited By...
The Nerve!: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.